HomeFinTechRecce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial

Recce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial

Date:

Revolut Expands Services: Users Can Now Send Money to China via Alipay

Revolut Enhances Global Transactions with New Alipay Integration for...

Consultation on the Future of Australian A2A Payments by AusPayNet and AP

Exploring Innovations and Developments in Account-to-Account Payment Systems Highlights: AusPayNet...

CastellumAI Raises $8.5M to Revolutionize AI in Real Estate

Empowering Real Estate with Innovative Artificial Intelligence Solutions Highlights: CastellumAI...

Recce Pharmaceuticals Selects CMAX for phase I/II UTI clinical trial

  • Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs)
  • The phase one and two intravenous clinical trial will assess RCE’s lead drug candidate, R327, in UTIs, with dosing to commence this quarter
  • Recce will collect plasma and urine from 12 healthy males and females following dosing to evaluate R327’s concentrations and antibacterial effect in the urine on bacteria
  • It follows an independent in-vitro study that found R327 had a fast effect against E. coli bacteria, which is responsible for around 90 per cent of UTIs
  • Recce shares are trading at 58 cents at midday AEDT
Exit mobile version